{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T08:47:01Z","timestamp":1790758021611,"version":"4.1.0"},"reference-count":5,"publisher":"Massachusetts Medical Society","issue":"26","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["N Engl J Med"],"published-print":{"date-parts":[[2019,12,26]]},"DOI":"10.1056\/nejmp1913547","type":"journal-article","created":{"date-parts":[[2019,10,30]],"date-time":"2019-10-30T17:01:38Z","timestamp":1572454898000},"page":"2491-2493","source":"Crossref","is-referenced-by-count":36,"title":["Where Were the Women? Gender Parity in Clinical Trials"],"prefix":"10.1056","volume":"381","author":[{"given":"Robert H.","family":"Goldstein","sequence":"first","affiliation":[{"name":"From the Division of Infectious Diseases, Department of Medicine (R.H.G., R.P.W.), and the Medical Practice Evaluation Center (R.P.W.), Massachusetts General Hospital, and the Harvard University Center for AIDS Research, Harvard Medical School (R.P.W.) \u2014 both in Boston."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rochelle P.","family":"Walensky","sequence":"additional","affiliation":[{"name":"From the Division of Infectious Diseases, Department of Medicine (R.H.G., R.P.W.), and the Medical Practice Evaluation Center (R.P.W.), Massachusetts General Hospital, and the Harvard University Center for AIDS Research, Harvard Medical School (R.P.W.) \u2014 both in Boston."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"150","reference":[{"key":"e_1_3_4_2_2","unstructured":"Guideline for the study and evaluation of gender differences in clinical evaluation of drugs; notice. Fed Regist 1993;58:39406-39416.11645233"},{"key":"e_1_3_4_3_2","unstructured":"FDA briefing document: meeting of the Antimicrobial Drugs Advisory Committee August 7 2019. Silver Spring MD: Food and Drug Administration (https:\/\/www.fda.gov\/media\/129607\/download)."},{"key":"e_1_3_4_4_2","unstructured":"Oakes K. FDA panel backs Descovy as HIV PrEP for men and transgender women who have sex with men. MDedge. August 7 2019 (https:\/\/www.mdedge.com\/infectiousdisease\/article\/206086\/hiv\/fda-panel-backs-descovy-hiv-prep-men-and-transgender-women-who)."},{"key":"e_1_3_4_5_2","unstructured":"FDA approves second drug to prevent HIV infection as part of ongoing efforts to end the HIV epidemic. Press release of the Food and Drug Administration October 3 2019 (https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-second-drug-prevent-hiv-infection-part-ongoing-efforts-end-hiv-epidemic)."},{"key":"e_1_3_4_6_2","unstructured":"Male breast cancer: developing drugs for treatment \u2014 guidance for industry. Silver Spring MD: Food and Drug Administration August 26 2019 (https:\/\/www.fda.gov\/media\/130061\/download)."}],"container-title":["New England Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nejm.org\/doi\/pdf\/10.1056\/NEJMp1913547","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T21:06:09Z","timestamp":1711487169000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.nejm.org\/doi\/10.1056\/NEJMp1913547"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,26]]},"references-count":5,"journal-issue":{"issue":"26","published-print":{"date-parts":[[2019,12,26]]}},"alternative-id":["10.1056\/NEJMp1913547"],"URL":"https:\/\/doi.org\/10.1056\/nejmp1913547","relation":{},"ISSN":["0028-4793","1533-4406"],"issn-type":[{"value":"0028-4793","type":"print"},{"value":"1533-4406","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,26]]}}}